Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inf...
January 11 2021 - 4:01PM
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a
commercial stage biotechnology company that aims to translate the
genetics of the adaptive immune system into clinical products to
diagnose and treat disease, today announced a translational
collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to investigate
the use of immunoSEQ T-MAP, a product that combines the sequencing
and mapping capabilities of Adaptive’s proprietary immune medicine
platform to map T-cell receptors (TCRs) to antigens, across
AstraZeneca’s oncology portfolio.
Under this collaboration, AstraZeneca will provide biological
samples from patients with cancer; Adaptive will sequence these
samples and deliver TCR-antigen mapping data using its growing and
dynamic clinical immunomics database of more than 58 billion immune
cell receptors and thousands of antigens. This mapping data may
inform signatures of immune response (or resistance) to cancer
therapies which may provide information to guide treatment
decisions. Additionally, mapping of unique TCRs to antigens at
scale can provide powerful information regarding the potential for
early and accurate detection of a disease and the specificity of a
given patient’s immune response to therapy.
“We continue to demonstrate that specific T-cell immune receptor
data can be utilized to inform the diagnosis and treatment for most
diseases,” said Sharon Benzeno, Chief Business Development Officer,
Adaptive Biotechnologies. “We are thrilled to partner with
AstraZeneca to realize the value of antigen-specific T-cell
response data across their portfolio of transformative cancer
medicines.”
Adaptive will receive from AstraZeneca quarterly payments plus
sequencing and data mapping fees. In addition, AstraZeneca has an
option to enter into a separate agreement with Adaptive for the
development and commercialization of a companion diagnostic or
therapeutic application based on T-MAP data. Specific financial
terms of the agreement will not be disclosed.
The scope of this non-exclusive, pan-portfolio oncology
collaboration may be expanded to cover additional therapeutic
areas, including autoimmunity and infectious diseases.
About Adaptive Adaptive Biotechnologies is
a commercial-stage biotechnology company focused on harnessing the
inherent biology of the adaptive immune system to transform the
diagnosis and treatment of disease. We believe the adaptive immune
system is nature’s most finely tuned diagnostic and therapeutic for
most diseases, but the inability to decode it has prevented the
medical community from fully leveraging its capabilities. Our
proprietary immune medicine platform reveals and translates the
massive genetics of the adaptive immune system with scale,
precision and speed to develop products in life sciences research,
clinical diagnostics, and drug discovery. We have three commercial
products, and a robust clinical pipeline to diagnose, monitor and
enable the treatment of diseases such as cancer, autoimmune
conditions and infectious diseases. Our goal is to develop and
commercialize immune-driven clinical products tailored to each
individual patient. For more information, please visit
adaptivebiotech.com and follow us on
www.twitter.com/adaptivebiotech.
Forward Looking StatementsThis press release
contains forward-looking statements that are based on management’s
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking
statements. These statements involve risks, uncertainties and
other factors that may cause actual results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements. These risks, uncertainties and other factors are
described under "Risk Factors," "Management's Discussion and
Analysis of Financial Condition and Results of Operations" and
elsewhere in the documents we file with the Securities and Exchange
Commission from time to time. We caution you that forward-looking
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. As a result, the forward-looking
statements may not prove to be accurate. The forward-looking
statements in this press release represent our views as of the date
hereof. We undertake no obligation to update any forward-looking
statements for any reason, except as required by law.
ADAPTIVE MEDIABeth
Keshishian917-912-7195media@adaptivebiotech.com
ADAPTIVE INVESTORSKarina Calzadilla, Vice
President, Investor Relations201-396-1687Carrie
Mendivil, Gilmartin Groupinvestors@adaptivebiotech.com
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Sep 2023 to Sep 2024